Introduction {#section9-2049936118808655}
============

Resistance to antibiotics has been steadily increasing, posing a growing worldwide health problem.

Methicillin-resistant *Staphylococcus aureus* (MRSA) has emerged as a common cause of complicated skin infections and pneumonia, among others, leading to the need for new effective and safe therapies.

Vancomycin remains the first option in the management of patients with invasive MRSA infections; however, renal toxicity, the narrow spectrum, low concentration in tissues, and an increase in resistance have warranted new treatment alternatives.

Ceftaroline fosamil is a cephalosporin antimicrobial that has generated much interest as a potential treatment option. However, detailed descriptions of its use remain limited.^[@bibr1-2049936118808655]^ As it is the case of other cephalosporins, the antibacterial activity of ceftaroline is the result of binding to essential penicillin-binding proteins (PBPs) inhibiting bacterial cell wall synthesis.^[@bibr1-2049936118808655],[@bibr2-2049936118808655]^

Ceftaroline has a broad spectrum of activity against clinically relevant gram-positive, strains including MRSA and resistant *Streptococcus pneumoniae* strains, as well as some gram-negative pathogens involved in complicated skin- and soft-tissue infections (cSSTI) and community-acquired pneumonia (CAP).^[@bibr3-2049936118808655],[@bibr4-2049936118808655]^ Currently, the drug has been approved by the US Food and Drug Administration (FDA) to be used in adults and children (from 2 months of age) with cSSTI caused by methicillin-sensitive and methicillin-resistant strains of *Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Klebsiella pneumoniae*, and *Klebsiella oxytoca*.^[@bibr1-2049936118808655][@bibr2-2049936118808655]--[@bibr3-2049936118808655]^ In addition, the drug has been approved by the FDA for CAP caused by *Streptococcus pneumoniae*, methicillin-sensitive, *Staphylococcus aureus* (non-MRSA), *Escherichia coli, Haemophilus influenzae, Klebsiella pneumonia*, and *Klebsiella oxytoca*.^[@bibr1-2049936118808655],[@bibr3-2049936118808655][@bibr4-2049936118808655]--[@bibr5-2049936118808655]^ Nevertheless, data on the clinical use of ceftaroline are scarce, especially in the pediatric population.^[@bibr5-2049936118808655]^

*Objective*: This systematic review was conducted to evaluate efficacy and safety of ceftaroline and to assess if the drug is associated with a lower rate of treatment failures compared to antibiotic comparators. The secondary aim was to assess effectiveness of the drug in infections in which MRSA was isolated.

Materials and methods {#section10-2049936118808655}
=====================

*Search strategies*: A literature search was conducted to identify all clinical trials comparing safety and efficacy of ceftaroline *versus* any or none comparator using the strategy described in [Table 1](#table1-2049936118808655){ref-type="table"}. Only articles published in English, Spanish, or French published up to 4 December 2017 were reviewed. Efficacy endpoint was the treatment failure rate because that is the main concern at the moment of antibiotic prescription. The safety endpoint was the incidence of adverse events.

###### 

Search strategy.

![](10.1177_2049936118808655-table1)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Database                                                                                                                                                Access platform                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Date of access    No. of results
  ------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- ----------------
  Medline                                                                                                                                                 Elsevier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  4 December 2017   49

  Embase                                                                                                                                                  Elsevier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  4 December 2017   68

  CINAHL                                                                                                                                                  EBSCOhost                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 4 December 2017   48

  Cochrane                                                                                                                                                Wiley Online Library                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      4 December 2017   59

  SCI-EXPANDED                                                                                                                                            WOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       4 December 2017   499

  Scopus                                                                                                                                                  Elsevier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  4 December 2017   918

  Total                                                                                                                                                   1641                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Duplicates                                                                                                                                              620                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Total without duplicates                                                                                                                                1021                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Medline (4 December 2017)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \#5                                                                                                                                                     \#4 AND (\[cochrane review\]/lim OR \[systematic review\]/lim OR \[meta analysis\]/lim OR \[randomized controlled trial\]/lim)                                                                                                                                                                                                                                                                                                                                                                                                            49                

  \#4                                                                                                                                                     \#3 AND \[medline\]/lim                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   812               

  \#3                                                                                                                                                     \#1 OR \#2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1299              

  \#2                                                                                                                                                     ceftaroline OR 'ceftaroline fosamil' OR teflaro OR zinforo:ab,ti                                                                                                                                                                                                                                                                                                                                                                                                                                                                          1299              

  \#1                                                                                                                                                     'ceftaroline'/mj OR 'ceftaroline fosamil'/mj                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              514               

  Embase (4 December 2017)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \#5                                                                                                                                                     \#4 AND (\[cochrane review\]/lim OR \[systematic review\]/lim OR \[meta analysis\]/lim OR \[randomized controlled trial\]/lim)                                                                                                                                                                                                                                                                                                                                                                                                            68                

  \#4                                                                                                                                                     \#3 AND \[embase\]/lim                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1263              

  \#3                                                                                                                                                     \#1 OR \#2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1299              

  \#2                                                                                                                                                     ceftaroline OR 'ceftaroline fosamil' OR teflaro OR zinforo:ab,ti                                                                                                                                                                                                                                                                                                                                                                                                                                                                          1299              

  \#1                                                                                                                                                     'ceftaroline'/mj OR 'ceftaroline fosamil'/mj                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              514               

  CINAHL (4 December 2017) Filtro de RR.SS y ECAs de SIGN. CINAHL (ECAs) for EBSCO (created by Mark Clowes) <http://www.sign.ac.uk/search-filters.html>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  S19                                                                                                                                                     S5 OR S18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 48                

  S18                                                                                                                                                     S1 AND S17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                46                

  S17                                                                                                                                                     S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1,298,037         

  S16                                                                                                                                                     TX allocat\* random\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     623               

  S15                                                                                                                                                     (MH 'Quantitative Studies')                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               17,078            

  S14                                                                                                                                                     (MH 'Placebos')                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           10,607            

  S13                                                                                                                                                     TX placebo\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              97,797            

  S12                                                                                                                                                     TX random\* allocat\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     11,005            

  S11                                                                                                                                                     (MH 'Random Assignment')                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  45,352            

  S10                                                                                                                                                     TX randomi\* control\* trial\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            189,585           

  S9                                                                                                                                                      TX ((singl\* n1 blind\*) or (singl\* n1 mask\*)) or TX ((doubl\* n1 blind\*) or (doubl\* n1 mask\*)) or TX ((tripl\* n1 blind\*) or (tripl\* n1 mask\*)) or TX ((trebl\* n1 blind\*) or (trebl\* n1 mask\*))                                                                                                                                                                                                                                                                                                                              952,488           

  S8                                                                                                                                                      TX clinic\* n1 trial\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    304,883           

  S7                                                                                                                                                      PT Clinical trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         85,443            

  S6                                                                                                                                                      (MH 'Clinical Trials +')                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  230,020           

  S5                                                                                                                                                      S1 AND S4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 10                

  S4                                                                                                                                                      S2 OR S3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  135,754           

  S3                                                                                                                                                      (MH 'Meta Analysis') or (TI (meta-analy\* or metaanaly\*)) or (AB (meta-analy\* or metaanaly\*))                                                                                                                                                                                                                                                                                                                                                                                                                                          53,544            

  S2                                                                                                                                                      (TI (systematic\* n3 review\*)) or (AB (systematic\* n3 review\*)) or (TI (systematic\* n3 bibliographic\*)) or (AB (systematic\* n3 bibliographic\*)) or (TI (systematic\* n3 literature)) or (AB (systematic\* n3 literature)) or (TI (comprehensive\* n3 literature)) or (AB (comprehensive\* n3 literature)) or (TI (comprehensive\* n3 bibliographic\*)) or (AB (comprehensive\* n3 bibliographic\*)) or (TI (integrative n3 review)) or (AB (integrative n3 review)) or (JN 'Cochrane Database of Systematic Reviews') or (TI ...   135,754           

  S1                                                                                                                                                      TI (ceftaroline OR 'ceftaroline fosamil' OR teflaro OR zinforo) OR AB (ceftaroline OR 'ceftaroline fosamil' OR teflaro OR zinforo)                                                                                                                                                                                                                                                                                                                                                                                                        83                

  Cochrane Library (4 December 2017)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  \#1                                                                                                                                                     ceftaroline or 'ceftaroline fosamil' or teflaro or zinforo:ti,ab,kw (Word variations have been searched)                                                                                                                                                                                                                                                                                                                                                                                                                                  59                

  Science Citation Index Expanded (SCI-EXPANDED; 4 December 2017)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \#1                                                                                                                                                     (TI = (ceftaroline OR 'ceftaroline fosamil' OR teflaro OR zinforo) OR TS = (ceftaroline OR 'ceftaroline fosamil' OR teflaro OR zinforo)) AND Idioma: (English OR Spanish) AND Tipos de documento: (Article OR Review)\                                                                                                                                                                                                                                                                                                                    499               
                                                                                                                                                          Índices = SCI-EXPANDED Período de tiempo = Todos los años                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Scopus (4 December 2017)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  5                                                                                                                                                       TITLE-ABS-KEY (ceftaroline OR 'ceftaroline fosamil' OR teflaro OR zinforo) AND (EXCLUDE (DOCTYPE, 'le') OR EXCLUDE (DOCTYPE, 'no') OR EXCLUDE (DOCTYPE, 'sh') OR EXCLUDE (DOCTYPE, 'ed') OR EXCLUDE (DOCTYPE, 'cp') OR EXCLUDE (DOCTYPE, 'ch')) AND (EXCLUDE (SUBJAREA, 'CHEM') OR EXCLUDE (SUBJAREA, 'AGRI') OR EXCLUDE (SUBJAREA, 'CENG') OR EXCLUDE (SUBJAREA, 'SOCI')) AND (EXCLUDE (SRCTYPE, 'k'))                                                                                                                                   918               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Study selection*: Data extraction and qualitative assessment were performed by two reviewers (M.T.R. and N.S.) who independently appraised the literature and considered only randomized controlled trials (RCTs) for further assessment. In case of disagreement, a third reviewer (R.L.) analyzed the data and managed the scientific discussion until consensus was reached.

A study qualified if (a) it was a RCT and (b) it compared the efficacy and safety of ceftaroline with other antibacterial agents or placebo. Both blinded and open-label trials were included. The methodological quality of the included studies was assessed using the Jadad scale.^[@bibr6-2049936118808655]^ The Jadad scale is a five-point questionnaire ([Table 2](#table2-2049936118808655){ref-type="table"}) in which each question is to be answered with either a yes or a no. Each yes scores a single point and each no, zero points. Trials scoring ⩾2 were considered for evaluation.

###### 

Jadad score template.

![](10.1177_2049936118808655-table2)

  ---------------------------------------------------------------------------------------------------------------------------------------------- -----
  Was the study described as randomized (this includes words such as randomly, random, and randomization)?                                       0/1
  Was the method used to generate the sequence of randomization described and appropriate (table of random numbers, computer-generated, etc.)?   0/1
  Was the study described as double blind?                                                                                                       0/1
  Was the method of double blinding described and appropriate (identical placebo, active placebo, dummy, etc.)?                                  0/1
  Was there a description of withdrawals and dropouts?                                                                                           0/1
  ---------------------------------------------------------------------------------------------------------------------------------------------- -----

*Data analysis and statistical methods*: Efficacy endpoint incidence was based on intention-to-treat (ITT) populations of each study, and relative risks were determined based on this measure. Pooled risk ratio (RR) and 95% confidence intervals (CIs) were calculated for failure and safety outcomes using the random-effects model (DerSimonian--Laird), in order to be more conservative. Calculations were carried out using the meta-analysis calculator by EpiData software version 3.1 (WHO). Heterogeneity bias was estimated using the *Q*-test. Potential publication bias was estimated using Egger's test. The null hypothesis was rejected if *p* value was less than 0.05. Systematic review was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement ([Table 3](#table3-2049936118808655){ref-type="table"}).

###### 

PRISMA checklist.

![](10.1177_2049936118808655-table3)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Section/topic                        \#   Checklist item                                                                                                                                                                                                                                                                                                   Reported on page \#
  ------------------------------------ ---- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  *Title*                                                                                                                                                                                                                                                                                                                                                    

  Title                                1    Identify the report as a systematic review, meta-analysis, or both.                                                                                                                                                                                                                                              \#1

  *Abstract*                                                                                                                                                                                                                                                                                                                                                 

  Structured summary                   2    Provide a structured summary including, as applicable, background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusion and implications of key findings; and systematic review registration number.   Abstract form\
                                                                                                                                                                                                                                                                                                                                                             \#1--2

  *Introduction*                                                                                                                                                                                                                                                                                                                                             

  Rationale                            3    Describe the rationale for the review in the context of what is already known.                                                                                                                                                                                                                                   Text\
                                                                                                                                                                                                                                                                                                                                                             \#1

  Objectives                           4    Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).                                                                                                                                                       Text\
                                                                                                                                                                                                                                                                                                                                                             \#1--2

  *Methods*                                                                                                                                                                                                                                                                                                                                                  

  Protocol and registration            5    Indicate if a review protocol exists, if and where it can be accessed (e.g. Web address), and, if available, provide registration information including registration number.                                                                                                                                     The protocol was not published

  Eligibility criteria                 6    Specify study characteristics (e.g. PICOS and length of follow up) and report characteristics (e.g. years considered, language, and publication status) used as criteria for eligibility, giving rationale.                                                                                                      \#2

  Information sources                  7    Describe all information sources (e.g. databases with dates of coverage and contact with study authors to identify additional studies) in the search and date last searched.                                                                                                                                     [Table 1](#table1-2049936118808655){ref-type="table"}

  Search                               8    Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.                                                                                                                                                                                    [Table 1](#table1-2049936118808655){ref-type="table"} and Methods section

  Study selection                      9    State the process for selecting studies (i.e. screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).                                                                                                                                                         \#3

  Data collection process              10   Describe method of data extraction from reports (e.g. piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.                                                                                                                                        [Figure 1](#fig1-2049936118808655){ref-type="fig"}\
                                                                                                                                                                                                                                                                                                                                                             \# 3

  Data items                           11   List and define all variables for which data were sought (e.g. PICOS and funding sources) and any assumptions and simplifications made.                                                                                                                                                                          \#3

  Risk of bias in individual studies   12   Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level) and how this information is to be used in any data synthesis.                                                                                            \#2--3--4

  Summary measures                     13   State the principal summary measures (e.g. risk ratio and difference in means).                                                                                                                                                                                                                                  \#3

  Synthesis of results                 14   Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g. I^[@bibr1-2049936118808655]^) for each meta-analysis.                                                                                                                                   \#3

  Risk of bias across studies          15   Specify any assessment of risk of bias that may affect the cumulative evidence (e.g. publication bias and selective reporting within studies).                                                                                                                                                                   \#3--5

  Additional analyses                  16   Describe methods of additional analyses (e.g. sensitivity or subgroup analyses and meta-regression), if done, indicating which were pre-specified.                                                                                                                                                               No

  *Results*                                                                                                                                                                                                                                                                                                                                                  

  Study selection                      17   Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.                                                                                                                                                  [Figure 1](#fig1-2049936118808655){ref-type="fig"}

  Study characteristics                18   For each study, present characteristics for which data were extracted (e.g. study size, PICOS, and follow-up period) and provide the citations.                                                                                                                                                                  [Table 4](#table4-2049936118808655){ref-type="table"}

  Risk of bias within studies          19   Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12).                                                                                                                                                                                                        [Tables 5](#table5-2049936118808655){ref-type="table"}--[6](#table6-2049936118808655){ref-type="table"}

  Results of individual studies        20   For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group; (b) effect estimates and confidence intervals, ideally with a forest plot.                                                                                                        [Tables 5](#table5-2049936118808655){ref-type="table"}--[6](#table6-2049936118808655){ref-type="table"}

  Synthesis of results                 21   Present results of each meta-analysis done, including confidence intervals and measures of consistency.                                                                                                                                                                                                          [Figure 2](#fig2-2049936118808655){ref-type="fig"}

  Risk of bias across studies          22   Present results of any assessment of risk of bias across studies (see item 15).                                                                                                                                                                                                                                  [Figure 2](#fig2-2049936118808655){ref-type="fig"}

  Additional analysis                  23   Give results of additional analyses, if done (e.g. sensitivity or subgroup analyses, and meta-regression (see item 16)).                                                                                                                                                                                         Not done

  *Discussion*                                                                                                                                                                                                                                                                                                                                               

  Summary of evidence                  24   Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g. healthcare providers, users, and policy makers).                                                                                                                              \#6--7

  Limitations                          25   Discuss limitations at study and outcome level (e.g. risk of bias) and at review level (e.g. incomplete retrieval of identified research and reporting bias).                                                                                                                                                    \#8

  Conclusion                           26   Provide a general interpretation of the results in the context of other evidence and implications for future research.                                                                                                                                                                                           \#9

  *Funding*                                                                                                                                                                                                                                                                                                                                                  

  Funding                              27   Describe sources of funding for the systematic review and other support (e.g. supply of data); role of funders for the systematic review.                                                                                                                                                                        Not funding
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Source*: Moher D, Liberati A, Tetzlaff J, *et al.*; The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 2009; 6: e1000097. DOI: 10.1371/journal.pmed1000097.

![Flow diagram of the process of identification and selection of the articles included.](10.1177_2049936118808655-fig1){#fig1-2049936118808655}

###### 

Main characteristics of the included studies.

![](10.1177_2049936118808655-table4)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                                 Study design                                                                          Intervention                                                                                                                                                                                                                                                 Endpoints                                                                           Jadad score
  ------------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------- -------------
  Talbot and colleagues^[@bibr7-2049936118808655]^        Randomized, observer-blinded trial                                                    Patients were randomized (2:1) to receive intravenous ceftaroline (*n* = 61) or vancomycin with or without adjunctive i.v. aztreonam (*n = *27) during 7--14 days.                                                                                           Clinical cure rate                                                                  2

  Wilcox and colleagues^[@bibr8-2049936118808655]^        Randomized, multinational,\                                                           Adult patients with cSSTI requiring intravenous therapy were randomized (1:1) to receive ceftaroline fosamil (*n* = 348) or vancomycin plus aztreonam (*n* = 346) during 5--14 days.                                                                         Clinical and microbiological response, adverse events, and laboratory tests         3
                                                          double-blind, active-controlled, parallel group                                                                                                                                                                                                                                                                                                                                                                                        

  Corey and colleagues^[@bibr9-2049936118808655]^         Randomized, multinational, double-blind, active-controlled, parallel group            Adult patients with cSSTI requiring intravenous therapy were randomized (1:1) to receive ceftaroline fosamil (*n* = 353) or vancomycin plus aztreonam (*n* = 349).                                                                                           Clinical and microbiological response, adverse events, and laboratory tests         3

  File and colleagues^[@bibr10-2049936118808655]^         Double-blinded, randomized, multinational trial                                       Adults hospitalized in a non-intensive care unit setting with CAP were randomized (1:1) to receive ceftaroline fosamil i.v. (*n* = 298) or ceftriaxone i.v. (*n* = 308) every 24 h.                                                                          Non-inferiority clinical cure, microbiological response, and adverse events         4

  Low and colleagues^[@bibr11-2049936118808655]^          Double-blinded, randomized, multinational trial                                       Hospitalized adults with CAP of PORT risk class III or IV severity were randomized (1:1) to receive ceftaroline fosamil (*n* = 315) or ceftriaxone (*n* = 307) administered during 5--7 days in non-ICU                                                      Non-inferiority clinical cure, microbiological response, and adverse events         4

  Zhong and colleagues^[@bibr12-2049936118808655]^        Randomized, controlled, double-blind, non-inferiority with nested superiority trial   Adults with risk class III--IV acute community-acquired pneumonia were randomly assigned (1:1) to receive intravenous ceftaroline fosamil (*n* = 381) or ceftriaxone (*n = *383) during 5--7 days.                                                           Clinically cured, microbiological cure, and adverse events                          4

  Korczowski and colleagues^[@bibr13-2049936118808655]^   Multicenter, randomized, observer-blinded, controlled trial                           Patients with cSSTI were randomized (2:1) to receive intravenous ceftaroline fosamil (*n* = 107) or IV vancomycin or cefazolin, ±aztreonam (*n* = 52)                                                                                                        Clinically cured, microbiological cure, and adverse events                          2

  Blumer and colleagues^[@bibr14-2049936118808655]^       Multicenter, randomized, observer-blinded, active-controlled trial                    Patients were randomized 3:1 (stratified by age cohort) to receive ceftaroline fosamil (*n* = 30) or ceftriaxone plus vancomycin (*n* = 10)                                                                                                                  Clinical cure rates, adverse events, and death                                      3

  Cannavino and colleagues^[@bibr15-2049936118808655]^    Multicenter, randomized, controlled trial                                             Patients were stratified into four age cohorts and randomized (3:1) to receive either intravenous ceftaroline fosamil (*n* = 122) or ceftriaxone (*n* = 69)                                                                                                  Treatment-emergent adverse events, clinical outcomes, and microbiologic responses   2

  Dryden and colleagues^[@bibr16-2049936118808655]^       Multicenter, randomized, double-blind, non-inferiority trial                          Patients with cSSTI and systemic inflammation or comorbidities were randomized (2:1) to 600 mg every 8 h of intravenous ceftaroline fosamil (*n* = 514) or 15 mg/kg every 12 h of vancomycin plus aztreonam (1 g every 8 h) (*n* = 258) during 5--14 days.   Clinically cured, microbiological cure, and adverse events                          4
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CAP, community-acquired pneumonia; cSSTI, complicated skin- and soft-tissue infections; ICU, intensive care unit; PORT, pneumonia outcome research trial.

###### 

Efficacy of the studies included: Therapeutic failure rate (intention-to-treat analyses).

![](10.1177_2049936118808655-table5)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                                  Ceftaroline (*n*/*N*)   Comparator (*n*/*N*)   RR (95% CI)           Weight (%; random-effects model)
  -------------------------------------------------------- ----------------------- ---------------------- --------------------- ----------------------------------
  Talbot and colleagues^[@bibr7-2049936118808655]^\        8/67                    6/32                   0.63 (0.24--1.68)     3.2587
  *n* = 99                                                                                                                      

  Wilcox and colleagues^[@bibr8-2049936118808655]^\        51/342                  49/338                 1.02 (0.71--1.47)     13.1184
  *n* = 680                                                                                                                     

  Corey and colleagues^[@bibr9-2049936118808655]^\         47/351                  50/347                 0.92 (0.64--1.34)     12.8584
  *n* = 698                                                                                                                     

  File and colleagues^[@bibr10-2049936118808655]^\         37/291                  67/300                 0.53 (0.37--0.75)     13.2904
  *n* = 591                                                                                                                     

  Low and colleagues^[@bibr11-2049936118808655]^\          54/289                  67/273                 0.76 (0.55--1.04)     14.7704
  *n* = 562                                                                                                                     

  Zhong and colleagues^[@bibr12-2049936118808655]^\        76/381                  126/382                0.60 (0.47--0.77)     17.7685
  *n* = 763                                                                                                                     

  Korczowski and colleagues^[@bibr13-2049936118808655]^\   16/107                  8/52                   0.97 (0.44--2.12)     4.7080
  *n* = 159                                                                                                                     

  Blumer and colleagues^[@bibr14-2049936118808655]^\       5/29                    2/9                    0.77 (0.18--3.33)     1.5529
  *n* = 38                                                                                                                      

  Cannavino and colleagues^[@bibr15-2049936118808655]^\    13/107                  4/36                   1.09 (0.38--3.14)     2.8151
  *n* = 143                                                                                                                     

  Dryden and colleagues^[@bibr16-2049936118808655]^\       110/506                 53/255                 1.04 (0.0.78--1.39)   15.8592
  *n* = 761                                                                                                                     

  Pooled RR (95% CI)\                                      *N* = 4494              0.79 (0.65--0.95)      100.00                
  random-effects model                                                                                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

CI, confidence interval; RR, risk ratio.

###### 

Safety of the studies included[\*](#table-fn5-2049936118808655){ref-type="table-fn"}.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                                  Ceftarolina (*n*/*N*)   Comparator (*n*/*N*)   RR (95% CI)         Weight (%) (random-effects model)
  -------------------------------------------------------- ----------------------- ---------------------- ------------------- -----------------------------------
  Talbot and colleagues^[@bibr7-2049936118808655]^\        41/67                   18/32                  1.09 (0.76--1.56)   5.2523
  *n* = 99                                                                                                                    

  Wilcox and colleagues^[@bibr8-2049936118808655]^\        64/341                  82/339                 0.96 (0.71--1.29)   9.84
  *n* = 680                                                                                                                   

  Corey and colleagues^[@bibr9-2049936118808655]^\         165/351                 167/347                0.95 (0.82--1.10)   19.2523
  *n* = 698                                                                                                                   

  File and colleagues^[@bibr10-2049936118808655]^\         119/298                 136/308                0.90 (0.75--1.09)   14.5085
  *n* = 591                                                                                                                   

  Low and colleagues^[@bibr11-2049936118808655]^\          64/315                  52/307                 1.20 (0.86--1.67)   6.0972
  *n* = 562                                                                                                                   

  Zhong and colleagues^[@bibr12-2049936118808655]^\        172/381                 163/383                1.06 (0.90--1.25)   17.5802
  *n* = 763                                                                                                                   

  Korczowski and colleagues^[@bibr13-2049936118808655]^\   23/106                  12/53                  0.96 (0.52--1.77)   1.9614
  *n* = 159                                                                                                                   

  Blumer and colleagues^[@bibr14-2049936118808655]^\       12/30                   8/10                   0.50 (0.29--0.86)   2.5391
  *n* = 38                                                                                                                    

  Cannavino and colleagues^[@bibr15-2049936118808655]^\    55/121                  18/39                  0.98 (0.67--1.46)   4.5392
  *n* = 143                                                                                                                   

  Dryden and colleagues^[@bibr16-2049936118808655]^\       142/506                 87/255                 0.82 (0.66--1.03)   11.6117
  *n* = 761                                                                                                                   

  Pooled RR (95% CI; random-effects model)                 *N* = 4589              0.98 (0.87--1.10)      100.00              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

CI, confidence interval; RR, risk ratio.

At least one adverse event.

![Risk of therapeutic failure: cumulative meta-analysis.\
Cumulative meta-analysis shows that the risk of therapeutic failure with ceftaroline is lower than with comparators, and this is a sustained trend.](10.1177_2049936118808655-fig2){#fig2-2049936118808655}

Results {#section11-2049936118808655}
=======

*Included studies and their main characteristics*: The literature search identified a total of 1021 potentially relevant abstracts. Screening by title and abstract, 30 RCTs were selected for initial evaluation. A total of 20 RCTs were excluded as they did not meet inclusion criteria or were duplications or new analysis of previously published studies. Finally, 10 full-text articles were selected to be potentially included in this review^[@bibr7-2049936118808655][@bibr8-2049936118808655][@bibr9-2049936118808655][@bibr10-2049936118808655][@bibr11-2049936118808655][@bibr12-2049936118808655][@bibr13-2049936118808655][@bibr14-2049936118808655][@bibr15-2049936118808655]--[@bibr16-2049936118808655]^ ([Figure 1](#fig1-2049936118808655){ref-type="fig"}).

Out of the 10 studies, three studies^[@bibr13-2049936118808655][@bibr14-2049936118808655]--[@bibr15-2049936118808655]^ were conducted in pediatric population (two for treatment of CAP^[@bibr14-2049936118808655],[@bibr15-2049936118808655]^ and one for cSSTI13); seven were carried out in adult patients^[@bibr7-2049936118808655][@bibr8-2049936118808655][@bibr9-2049936118808655][@bibr10-2049936118808655][@bibr11-2049936118808655]--[@bibr12-2049936118808655]^ (four for cSSTI and three for the treatment of CAP).

[Table 4](#table4-2049936118808655){ref-type="table"} summarizes the main characteristics of the articles included, and [Table 5](#table5-2049936118808655){ref-type="table"} shows the effect size, the proportional weight, and the pooled RR (95% CI) for the risk of failure of each study. Even when no heterogeneity was detected, pooled RR was calculated using the random-effects model (DerSimonian--Laird).

In individual studies, ceftaroline performance in CAP and cSSTI was not notably better than comparators regardless of the microbiological features ([Table 6](#table6-2049936118808655){ref-type="table"}). However, cumulative meta-analysis revealed a lower risk of therapeutic failure for ceftaroline and the effect size became more relevant and precise when sample size increased, showing a sustained trend as in [Figure 2](#fig2-2049936118808655){ref-type="fig"}.

Rates of adverse events were similar among the studies and there were no statistically significant differences between groups; however, significant heterogeneity among studies (*p* = 0.03) was found for this endpoint. Pooled RR for adverse events was 0.98 (95% CI = 0.87--1.10). The most commonly reported adverse drug reactions for ceftaroline were rash, fever, and gastrointestinal symptoms.^[@bibr7-2049936118808655][@bibr8-2049936118808655][@bibr9-2049936118808655][@bibr10-2049936118808655][@bibr11-2049936118808655][@bibr12-2049936118808655][@bibr13-2049936118808655][@bibr14-2049936118808655][@bibr15-2049936118808655]--[@bibr16-2049936118808655]^

In the majority of studies, the rate of direct Coombs test seroconversion was higher in the ceftaroline group than in the comparator groups. Nevertheless, no cases of hemolytic anemia were reported.

In order to analyze risk of treatment failure specifically in infections due to MRSA, a secondary analysis was performed including the six studies (357 patients) reporting these data.^[@bibr7-2049936118808655][@bibr8-2049936118808655]--[@bibr9-2049936118808655]^,^[@bibr12-2049936118808655],[@bibr13-2049936118808655],[@bibr16-2049936118808655]^ Pooled RR was 0.71 (95% CI = 0.37--1.35).

No significant publication bias was detected (*p* \> 0.05) at any stage (efficacy or safety analysis) of the meta-analysis, although its probability is close to the boundary of significance. [Figure 3](#fig3-2049936118808655){ref-type="fig"} shows the corresponding funnel plot for efficacy analysis (*Q*-test: 16.46; *p* = 0.058).

![Risk of publication bias in efficacy analysis.\
Figure 3 presents the corresponding funnel plot for efficacy analysis (*Q*-test: 16.46; *p* = 0.058).](10.1177_2049936118808655-fig3){#fig3-2049936118808655}

In other infections, such as endocarditis, osteoarticular infections, and bacteremia, only case series showing good results with ceftaroline fosamil were found;^[@bibr17-2049936118808655][@bibr18-2049936118808655][@bibr19-2049936118808655][@bibr20-2049936118808655]--[@bibr21-2049936118808655]^ however, these studies were not analyzed in this study.

Discussion {#section12-2049936118808655}
==========

This systematic review was conducted to evaluate the risk of therapeutic failure and safety of ceftaroline in children and adults in order to assess the comparative effectiveness and safety of the drug as monotherapy against available comparators.

This meta-analysis suggests that ceftaroline was effective and well tolerated, consistent with the good safety profile of the cephalosporins.^[@bibr22-2049936118808655]^ This finding, which does not arise from the observation of the individual studies, is probably the result of the increasing sample size.

It is worth pointing out that the risk of therapeutic failure of ceftaroline was found to be significantly lower for both types of infection, and a sustained trend was seen in the cumulative meta-analysis.

Concerns arose, when all the included RCT studies were observed to be conducted only in patients with CAP or cSSTI infections, in patients who were not admitted to intensive care units (ICUs) or were treated with different doses having different follow-up periods, or were using antibiotic comparators that are not typically indicated in the clinics for the treatment of these infections, among others' characteristics.

In CAP, ceftriaxone is the only cephalosporin that has been demonstrated superiority to penicillin in *Streptococcus pneumoniae*, even in penicillin-resistant strains, and the drug may be an option in these cases.^[@bibr8-2049936118808655]^ Ceftaroline may be useful against gram-positive organisms and in areas with a high incidence of MRSA infections.

For complicated pneumonia and patients in the ICU, antimicrobial therapy must be broadened to cover pathogens such as MRSA.

The study by Zhong and colleagues^[@bibr12-2049936118808655]^ was the only report that found non-inferiority, even superiority, of ceftaroline *versus* ceftriaxone for the management of CAP in Asian patients not admitted to the ICU. However, the conclusions of this study are of limited validity because of the observed risk of bias regarding the timing of assessment of clinical cure between groups, doses, and conflict of interest, among others' concerns.^[@bibr23-2049936118808655]^

In other infections such as endocarditis, osteoarticular infections, and bacteremia, only case series showing good results with ceftaroline fosamil were found,^[@bibr17-2049936118808655][@bibr18-2049936118808655][@bibr19-2049936118808655][@bibr20-2049936118808655]--[@bibr21-2049936118808655]^ but these reports were not analyzed in this study.

The strengths of our study are that, to the best of our knowledge, this is the first systematic review and meta-analysis on the efficacy and safety of ceftaroline including children and adults, only RCTs were included, and that the quality of the studies included was assessed in detail.

Limitations are that no RCTs including other non-cSSTI and non-CAP infections were found, cases in which MRSA was isolated were few, and none of the patients was admitted to the ICU. Quality of evidence of studies carried out in other types of infection or in patients admitted to the ICU was limited. In addition, very few studies were conducted in children.

Inherent to systematic reviews, publication bias is always a potential problem, and although the comprehensive search strategy may overcome this issue and the funnel plot showed no relevant evidence of publication bias, this possibility can never be completely excluded.

*Clinical implications*: The superior efficacy of ceftaroline, its safety profile, and the possibility of its use as monotherapy decrease the need for combined antibiotic treatments, making the drug an attractive option in clinical practice.

Ceftaroline may be considered, particularly in patients with CAP and cSSTI that are intolerant or refractory to other antibiotics used as first-line treatment.

It is remarkable that none of the patients was studied in an ICU setting; however, given the effectiveness of ceftaroline, it may be speculated that even in patients admitted to the ICU, ceftaroline could be useful.

*Future research*: Further randomized and controlled studies are needed to better understand the role of ceftaroline in other non-CAP and non-cSSTI infections in ICU settings and in children.
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